Related Experiment Video
Updated: Feb 11, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
The decrease of glycolytic enzyme hexokinase 1 accelerates tumor malignancy via deregulating energy metabolism but
Po-Lin Tseng1,2, Chih-Wei Chen3,4,5, Keng-Hsun Hu6
1Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan 302, Taiwan.
Abstract:
Malignant tumors often display an aberrant energy metabolism that relies primarily on glycolysis to produce adenosine triphosphate (ATP) the so-called Warburg effect or aerobic glycolysis. Thus, the elucidation of this energetic alteration in malignant tumors is important in the search for more effective therapeutics against malignant cancers, the most deadly human disease. To investigate whether attenuated glycolytic activity modulates tumor progression, the effects of silencing the first and rate-limiting glycolytic enzyme hexokinase (HK) isozymes HK1 and HK2 were examined. There was an inverse correlation between the expression of HK1 and HK2 in human cancer cells. In cervical carcinoma cells, the HK1 but not HK2 knockdown induced a phenotypic change characteristic of epithelial-mesenchymal transition, which accelerated tumor growth and metastasis both in vitro and in vivo analyses. Notably, the silencing of HK1 disrupted aerobic respiration and increased glycolysis, but it had no effect on ATP generation. These metabolic changes were associated with higher HK2 and lactate dehydrogenase 1 expression but a lower citrate synthase level. Particularly, the HK1 knockdown induced aberrant energy metabolism that was almost recapitulated by HK2 overexpression. Moreover, the HK1-silenced cells showed strong glucose-dependent growth and 2-deoxyglucose (2-DG) induced cell proliferation inhibition. These results clearly indicate that the silencing of HK1, but not HK2, alters energy metabolism and induces an EMT phenotype, which enhances tumor malignancy, but increases the susceptibility of cancer cells to 2-DG inhibition. In addition, this work also suggests that the glycolytic inhibitors should be used only to treat cancers with elevated glycolytic activity.
Insights
Silencing hexokinase 1 (HK1) in cancer cells alters energy metabolism, promoting tumor growth and metastasis. However, HK1-silenced cells become more vulnerable to 2-deoxyglucose (2-DG) treatment, suggesting targeted therapies.
Area of Science:
- Cancer Biology
- Metabolic Reprogramming
- Tumorigenesis
Background:
- Malignant tumors exhibit altered energy metabolism, primarily glycolysis (Warburg effect), for adenosine triphosphate (ATP) production.
- Understanding these metabolic shifts is crucial for developing effective anti-cancer therapeutics.
- Hexokinase (HK) enzymes are key regulators of glycolysis.
Purpose of the Study:
- To investigate the role of attenuating glycolytic activity by silencing hexokinase (HK) isozymes HK1 and HK2 in tumor progression.
- To explore the impact of HK1 and HK2 modulation on cancer cell metabolism, phenotype, and therapeutic susceptibility.
Main Methods:
- Examined the effects of silencing hexokinase (HK) isozymes HK1 and HK2 in human cancer cells, specifically cervical carcinoma.
- Utilized in vitro and in vivo analyses to assess tumor growth, metastasis, and phenotypic changes (epithelial-mesenchymal transition).
- Analyzed cellular energy metabolism, including aerobic respiration, glycolysis, ATP generation, and key enzyme expression levels (HK1, HK2, lactate dehydrogenase 1, citrate synthase).
Main Results:
- Silencing HK1, but not HK2, induced an epithelial-mesenchymal transition (EMT) phenotype, accelerating tumor growth and metastasis.
- HK1 knockdown disrupted aerobic respiration, increased glycolysis, and enhanced glucose dependency without affecting ATP levels.
- HK1-silenced cells showed increased susceptibility to 2-deoxyglucose (2-DG) induced proliferation inhibition.
Conclusions:
- Silencing HK1 significantly alters cancer cell energy metabolism and promotes malignancy via EMT, while increasing sensitivity to 2-DG.
- The study highlights an inverse correlation between HK1 and HK2 expression in cancer cells.
- Results suggest that glycolytic inhibitors like 2-DG may be effective for cancers with elevated glycolytic activity, specifically those influenced by HK1.
Related Concept Videos
Enzyme Inhibition
Enzymes and Activation Energy
Feedback Inhibition
Enzymes
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Energy-requiring Steps of Glycolysis
Predicting Products: SN1 vs. SN2
With increased substitution on the alkyl halide,...

